Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
Consero Healthcare General Counsel Forum 2026
Sponsorship
Antitrust
Energizing Tomorrow: The Future of Energy, Antitrust & International Business Law
Sponsorship
Antitrust
IBA Annual Conference 2026
Sponsorship
Antitrust
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
Axinn Partners Named to Lawdragon’s 2027 500 “Leading Litigators in America” Guide
Awards & Recognitions
Antitrust
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
The DOJ’s Antitrust Whistleblower Rewards Program
Webinar
Antitrust

